Baudax Bio, Inc. (BXRX)

Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition

FDA grants the Orphan Drug designation to Baudax (BXRX) for its lead pipeline candidate, TI-168, to treat Hemophilia A patients with inhibitors.

As the market attempted to recover from a recent series of disappointing performances, biotechnology firm Baudax Bio (NASDAQ: BXRX ) represented a dramatic winner. Earlier Thursday morning, management disclosed that the U.S. Food and Drug Administration (FDA) granted its lead clinical candidate orphan drug designation.

Shares of Baudax Bio added 80% after it announced its lead clinical candidate targeting Hemophilia A with inhibitors has been awarded orphan drug status by the United States Food and Drug Administration (FDA). Its lead candidate TI-168 is a FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors.

MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is the Company's next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors.

Baudax Bio, Inc. (BXRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

MALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that that the Company's management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13, 2023 in New York, NY.

MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on September 5, 2023. The shares of Series C Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on September 7, 2023. The outstanding shares of Series C Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single class, exclusively with respect to a proposal to approve a reverse stock split, as well as any proposal to adjourn any meeting of shareholders called for the purpose of voting on the reverse stock split, and will not be entitled to vote on any other matter, except to the extent required under the Pennsylvania Business Corporation Law. Subject to certain limitations, each outstanding share of Series C Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Series C Preferred Stock).

MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (Nasdaq: BXRX), a biotechnology company focused on developing T cell receptor therapies utilizing human regulatory T cells, as well as a portfolio of clinical stage Neuromuscular Blocking Agents and an associated reversal agent, today announced that it has entered into definitive agreements for the purchase and sale of 2,006,544 shares of its common stock and 1,395,243 Series E pre-funded warrants at a purchase price of $0.56 per share of common stock (or $0.55 per prefunded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered series A-7 common stock purchase warrants (the “warrants”) to purchase up to 3,401,787 shares of common stock. The warrants have an initial exercise price of $0.56 per share and are not exercisable until the shareholders of the Company approve the issuance of the underlying shares (the “Approval”). The warrants are exercisable for a period of five years commencing from the date the Approval is obtained. Additionally, the exercise price of the warrants will be adjusted upon the Company effecting a reverse stock split, if the post-reverse stock split exercise price of the warrants is higher than the lowest daily VWAP of the common stock during the five trading days following the reverse stock split (the “Adjustment”). If the Adjustment is applicable, the exercise price of the warrants will be reduced to the lowest daily VWAP of the common stock during the five trading days following such reverse stock split, and the number of shares issuable upon exercise of the warrants shall increase such that the aggregate exercise price payable as a result of such Adjustment shall be equal to the aggregate exercise price payable prior to such Adjustment. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about August 21, 2023, subject to the satisfaction of customary closing conditions.

Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to Advance Neuromuscular Blockade (NMB) Portfolio at Modest Pace Announcement of Positive Top-Line Results from Phase 2 BX1000 Trial MALVERN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) --  Baudax Bio, Inc. (Nasdaq:BXRX) (“Baudax Bio” or the “Company”), is a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced results for the three and six months ended June 30, 2023 and provided a business update.

Baudax Bio (BXRX) soars on the acquisition of a private company, TeraImmune. The acquisition will help advance novel cell therapies for autoimmune diseases.

Against a broadly positive backdrop due to cooling inflation data, Baudax Bio (NASDAQ: BXRX ) nevertheless managed to resoundingly steal the spotlight, skyrocketing into triple-digit percentage gains. The pharmaceutical company — which focuses on innovative products for acute care — announced the acquisition of Teralmmune, a privately held biotechnology firm focused on autoimmune disease therapies.

Shares of Baudax Bio BXRX, -1.85% jumped 25% premarket on Friday after the company announced the acquisition of TeraImmune, a privately held biotech developing Treg-based cell therapies for autoimmune diseases. TeraImmune has a cell therapy candidate to eliminate certain clotting factor inhibitors in patients with hemophilia A, a rare genetic bleeding disorder, Baudax said in a release.

New data from Baudax's (BXRX) study on BX1000 confirms greater comparability of the highest dose of the candidate to the standard dose of rocuronium as a neuromuscular blockade. Stock gains 4%.

MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, recently announced that it has adjourned its Annual Meeting of Shareholders (the “Annual Meeting”) without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum.

MALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place May 10-11, 2023.